播放中国国产国语纯一级黄片免费看, 大鸡吧快来啊阿啊阿啊黄片在线播放, 中文精品日韩网站在线观看视频免费, 别揉我奶头~嗯~啊~一区二区三区,AV无码播放一级毛片免费古装,亚洲春色一区二区三区,91大神极品,美国一级大黄一片免费下载,午夜爽爽爽男女免费观看软件

Welcome to LookChem.com Sign In|Join Free

CAS

  • or
5-Fluoro-2-nitrobenzoic acid is an ortho-nitro benzoic acid derivative, which can be synthesized by the oxidation of 5-fluoro-2-nitrotoluene. It is a white to light yellow crystal powder and serves as an intermediate in the synthesis of N1-(2,4-dichlorophenyl)-2-amino-5-fluorobenzamide. 5-Fluoro-2-nitrobenzoic acid also plays a role in the creation of novel quinazolinones, which are potential inhibitors of p38α mitogen-activated protein kinase (MAPK).

320-98-9

Post Buying Request

320-98-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

320-98-9 Usage

Uses

Used in Pharmaceutical Industry:
5-Fluoro-2-nitrobenzoic acid is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its primary application is in the production of N1-(2,4-dichlorophenyl)-2-amino-5-fluorobenzamide, a compound with potential therapeutic properties.
Used in Research and Development:
In the field of research and development, 5-Fluoro-2-nitrobenzoic acid is utilized for the synthesis of novel quinazolinones. These quinazolinones are being investigated for their potential as inhibitors of p38α mitogen-activated protein kinase (MAPK), which is a key enzyme involved in various cellular processes and may play a role in the development of certain diseases.
Used in Chemical Synthesis:
5-Fluoro-2-nitrobenzoic acid is also used as a starting material or building block in the chemical synthesis of other complex organic compounds. Its unique structure and functional groups make it a valuable component in the creation of new molecules with specific properties and applications.

Check Digit Verification of cas no

The CAS Registry Mumber 320-98-9 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 3,2 and 0 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 320-98:
(5*3)+(4*2)+(3*0)+(2*9)+(1*8)=49
49 % 10 = 9
So 320-98-9 is a valid CAS Registry Number.
InChI:InChI=1/C7H4FNO4/c8-4-1-2-6(9(12)13)5(3-4)7(10)11/h1-3H,(H,10,11)/p-1

320-98-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-Fluoro-2-nitrobenzoic acid

1.2 Other means of identification

Product number -
Other names 5-Fluoro-2-Nitrobenzoic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:320-98-9 SDS

320-98-9Relevant articles and documents

2-((3,5-Dinitrobenzyl)thio)quinazolinones: Potent Antimycobacterial Agents Activated by Deazaflavin (F420)-Dependent Nitroreductase (Ddn)

Jian, Yanlin,Forbes, He Eun,Hulpia, Fabian,Risseeuw, Martijn D. P.,Caljon, Guy,Munier-Lehmann, Hélène,Boshoff, Helena I. M.,Van Calenbergh, Serge

, p. 440 - 457 (2021/01/14)

Swapping the substituents in positions 2 and 4 of the previously synthesized but yet undisclosed 5-cyano-4-(methylthio)-2-arylpyrimidin-6-ones 4, ring closure, and further optimization led to the identification of the potent antitubercular 2-thio-substituted quinazolinone 26. Structure-activity relationship (SAR) studies indicated a crucial role for both meta-nitro substituents for antitubercular activity, while the introduction of polar substituents on the quinazolinone core allowed reduction of bovine serum albumin (BSA) binding (63c, 63d). While most of the tested quinazolinones exhibited no cytotoxicity against MRC-5, the most potent compound 26 was found to be mutagenic via the Ames test. This analogue exhibited moderate inhibitory potency against Mycobacterium tuberculosis thymidylate kinase, the target of the 3-cyanopyridones that lies at the basis of the current analogues, indicating that the whole-cell antimycobacterial activity of the present S-substituted thioquinazolinones is likely due to modulation of alternative or additional targets. Diminished antimycobacterial activity was observed against mutants affected in cofactor F420 biosynthesis (fbiC), cofactor reduction (fgd), or deazaflavin-dependent nitroreductase activity (rv3547), indicating that reductive activation of the 3,5-dinitrobenzyl analogues is key to antimycobacterial activity.

Synthesis of novel quinazolinone derivatives with methyl (E)-2-(3-methoxy)acrylate moiety

Dong, Kui-Kui,Zhou, Hua-Hong,Guo, A-Rong,Chen, Tian,Wang, Yu-Liang

, p. 1039 - 1042 (2013/05/08)

A new series of quinazolinone derivatives with methyl (E)-2-(3-methoxy) acrylate moiety have been designed and synthesized. All target compounds had been identified by 1H NMR spectrum, IR spectrum and HR-MS (high resolution mass spectrum). Three target compounds (10a, 10e, 10h) were chosen to preliminarily test the antibacterial activities, the results showed that all three target compounds exhibited antibacterial activities against three bacterial strains (Proteobacteria, Salmonella, Colibacillus).

INHIBITORS OF STEAROYL-COA DESATURASE

-

, (2009/06/27)

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.

TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES

-

Page/Page column 43, (2008/12/06)

treatment of a variety of disorders, including the treatment of pathological conditions associated with tumor necrosis factor alpha. The inhibitors of tumor necrosis factor alpha have the following structures: including stereoisomers, pharmaceutically acceptable salts, and solvates thereof, wherein substituents are as defined herein. Compositions containing an inhibitor of tumor necrosis factor alpha in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

Neuroprotective small organic molecules, compositions and uses related thereto

-

Page/Page column sheet 2; 44-45, (2008/06/13)

The present application is directed to therapeutic compounds, compositions, and methods for culturing neuronal cells and for preventing and the treatment of neurodegenerative diseases, such as Parkinson's disease and amyotrophic lateral sclerosis (ALS).

Synthesis and biological evaluation of anthranilamide-based non-peptide mimetics of ω-conotoxin GVIA

Baell, Jonathan B.,Duggan, Peter J.,Forsyth, Stewart A.,Lewis, Richard J.,Lok, Y. Phei,Schroeder, Christina I.,Shepherd, Nicholas E.

, p. 7284 - 7292 (2007/10/03)

Non-peptide mimetics based on an anthranilamide 'scaffold' possessing fragments that mimic Lys2, Tyr13 and Arg17 in ω-conotoxin GVIA have been prepared. Compounds were assayed for binding to the voltage-gated calcium channels Cav2.2 ('N-type')

2- (4-0X0-4H-QUINAZ0LIN-3-YL) ACETAMIDES AND THEIR USE AS VASOPRESSIN V3 ANTAGONISTS

-

Page/Page column 41, (2010/11/23)

The present invention relates to 2-(4-oxo4H-quinazolin-3-yl)acetamicle derivatives of formula (I), and to their use as vasopressin V3 antagonists, particularly for the treatment of depression.

INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME

-

Page 106, (2010/02/08)

Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures (Ia), (Ib) including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

2-ureido-benzamide derivatives

-

, (2008/06/13)

This invention is concerned with 2-ureido-benzamide compounds of the formula (1) STR1 in which R1 is H, halogen atom, (C1 -C4)alkyl, (C1 -C4)alkoxy or (C1 -C4)dialkylamino and R2 is H, halogen atom, hydroxy, nitro, (C1 -C4)alkyl, (C1 -C4)alkoxy, (C3 -C6) cycloalkylmethoxy, (C1 -C4) alkylthio, (C1 -C4) alkylsulfinyl, (C1 -C4)alkylsulfonyl or STR2 wherein j is an integer of from 0 to 2 and R3 and R4 are each independently H, (C1 -C4)alkyl, (C1 -C4)alkanoyl, (C1 -C4)alkylsulfonyl or (C1 -C4)alkylcarbamoyl, NR3 R4 can to form a pyrrolidine, piperidine, morpholine, imidazole or pyrazole ring; X is a (C3 -C15)alkyl, (C3 -C6) cycloalkyl, (C3 -C6) cycloalkylmethyl, ω-(C1 -C4) alkoxy-(C1 -C4) alkyl group or STR3 wherein k is an integer of from 1 to 4 and R5 and R6 are each independently H, Y is H or (C1 -C4)alkyl and Z is STR4 wherein m is an integer of from 0 to 4.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 320-98-9